Therapeutic Asset Ratings
141 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Ptm-101
Pancreatic Ductal Adenocarcinoma
PanTher Therapeutics
P1
C
(37)
rad301
Pancreatic Ductal Adenocarcinoma
Radiopharm Theranostics, Ltd
P1
C
(37)
Sargramostim
Pancreatic Ductal Adenocarcinoma
National Cancer Institute (NCI)
P1
C
(37)
SX682
Pancreatic Ductal Adenocarcinoma
University of Rochester
P1
C
(37)
Tas-102
Pancreatic Ductal Adenocarcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
Tas-115
Pancreatic Ductal Adenocarcinoma
Taiho Pharmaceutical Co., Ltd.
P1
C
(37)
Vsv-Gp154
Pancreatic Ductal Adenocarcinoma
Boehringer Ingelheim
P1
C
(37)
Evolocumab
Pancreatic Ductal Adenocarcinoma
CHU de Quebec-Universite Laval
Early P1
C
(34)
Ezetimibe
Pancreatic Ductal Adenocarcinoma
CHU de Quebec-Universite Laval
Early P1
C
(34)
HUMAN FAECAL MATTER
Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Early P1
C
(34)
Hydroxychloroquine
Pancreatic Ductal Adenocarcinoma
Fox Chase Cancer Center
Early P1
C
(34)
Ketorolac Tromethamine
Pancreatic Ductal Adenocarcinoma
Andrew Hendifar, MD
Early P1
C
(34)
Lipitor
Pancreatic Ductal Adenocarcinoma
CHU de Quebec-Universite Laval
Early P1
C
(34)
GLUCOSE, ANHYDROUS
Pancreatic Ductal Adenocarcinoma
Rutgers, The State University of New Jersey
N/A
D
(28)
ROPIVACAINE
Pancreatic Ductal Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University
N/A
D
(28)
Secretin
Pancreatic Ductal Adenocarcinoma
Adenocyte, LLC
D
(28)
Showing 126 to 141 of 141 assets
Previous
Page 6 of 6
Next
